Haemonetics Corporation 10-Q Summary
Business Context and Reporting Period
Haemonetics Corporation designs, manufactures, and markets automated blood processing systems. This report covers the three and six months ended September 27, 2003 (Fiscal Year 2004). The company operates as a single segment, with approximately 64% of sales generated internationally, primarily in Europe and Japan.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended Sep 27, 2003 | 6 Months Ended Sep 27, 2003 |
|---|---|---|
| Net Revenues | $87,488 | $175,771 |
| Gross Profit | $41,380 (47.3% margin) | $80,966 (46.1% margin) |
| Operating Income | $8,906 (10.2% margin) | $17,092 (9.7% margin) |
| Net Income | $5,495 | $10,478 |
| Diluted EPS | $0.23 | $0.43 |
| Cash from Operations | N/A | $22,758 |
| Cash & Equivalents | $66,771 | $66,771 |
| Total Debt (Current + Long-term) | $69,777 | $69,777 |
Material Changes vs. Prior Period
- Revenue: Net revenues increased 0.5% ($0.5M) for the quarter and 4.0% ($6.8M) for the six months compared to the prior year. Growth was driven by volume increases in disposable sales and favorable foreign currency effects, offset by a significant decline in equipment sales.
- Profitability: Gross profit margins improved to 47.3% (quarter) and 46.1% (six months) due to cost reductions from the "CORE" program and favorable currency impacts. However, operating income decreased 9.4% for the quarter and 12.4% for the six months.
- Expenses: Selling, general, and administrative (SG&A) expenses increased significantly due to a $2.6 million reorganization charge (severance costs) and foreign currency translation. Research and development expenses decreased due to lower headcount.
- Cash Flow: Net cash provided by operating activities increased to $22.8 million for the six months ended September 27, 2003, compared to $12.1 million in the prior year, driven by improved working capital management.
Guidance, Outlook, and Risks
- Reorganization: The company announced a reorganization to align with "Donor" and "Patient" customer categories, reducing the workforce by approximately 4%. A review of strategic initiatives is ongoing, which may lead to impairments of long-term assets.
- Customer Consolidation Risk: Baxter Healthcare acquired Alpha Therapeutics, a significant Plasma customer. Baxter intends to close 38 of 41 acquired centers. While Haemonetics has supply contracts with exclusivity and minimum purchase requirements, the impact on future revenue is currently unknown.
- Foreign Exchange: Approximately 64% of sales are international. The company uses forward contracts to hedge currency risk. A 10% strengthening of the U.S. dollar would increase the fair value of forward contracts by $12.4 million.
- Tax Rate: Management expects an effective tax rate of 36% for the remainder of fiscal 2004, up from 31% in the prior year due to changes in tax-efficient cash repatriations and export credits.
Investor Verification Checklist
- Verify the impact of the Baxter/Alpha Therapeutics consolidation on future Plasma disposable sales volumes.
- Monitor the completion of the strategic review and potential impairment charges related to long-term assets.
- Track the execution of the "CORE" cost reduction program to ensure sustained gross margin improvements.
- Assess the stability of equipment sales, which are highly variable and declined significantly year-over-year.
- Review foreign currency hedge positions given the company's high exposure to the Euro and Japanese Yen.